Skip to main
  1. Stocks
  2. Doximity
  3. Forecast
DOCS

Doximity (DOCS) Stock Forecast & Price Target

Doximity (DOCS) Analyst Ratings

Based on 21 analyst ratings
Hold
Strong Buy 19%
Buy 24%
Hold 48%
Sell 10%
Strong Sell 0%

Bulls say

Doximity is well positioned because its platform reaches roughly 80% of U.S. physicians, creating a durable network moat that supports sticky Marketing, Hiring, and Workflow Solutions and gives pharma customers efficient access to highly targeted medical audiences. The business is also proving strong operating leverage, with revenue of $174.5M (+4% y/y), adjusted EBITDA of $88.9M at a 50.9% margin, and free cash flow of $91M, while AI Search has already become an eight-figure bookings product with 16 of the top 20 pharma companies buying in. Management’s raised FY27 revenue outlook to $678M-$683M, plus expanding health system adoption and improving AI unit costs, suggests the company can sustain growth while investing for a larger AI-driven opportunity.

Bears say

Doximity is exposed to a concentrated revenue base, with over 90% of sales tied to marketing solutions sold to pharma and health systems, leaving results highly dependent on cyclical drug budgets rather than on diversified demand. Its core customer spend is pressured by Most Favored Nation pricing uncertainty, Inflationary Reduction Act-related reprioritization, FDA scrutiny, and upcoming LOEs, while most contracts are only 12 months or less, so renewals and bookings can shift quickly. Although the platform reaches 85% of all doctors, low switching costs, data-privacy limits, cybersecurity risk, and the possibility that AI investments fail to offset weaker HCP pharma marketing create an unattractive risk/reward profile.

Doximity (DOCS) has been analyzed by 21 analysts, with a consensus rating of Hold. 19% of analysts recommend a Strong Buy, 24% recommend Buy, 48% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Doximity and is not a guaranteed prediction by Public.com or investment advice.

Doximity (DOCS) Analyst Forecast & Price Prediction

Get the latest Doximity (DOCS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Doximity (DOCS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Doximity (DOCS) Forecast

Analysts have given Doximity (DOCS) a Hold based on their latest research and market trends.

According to 21 analysts, Doximity (DOCS) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Doximity (DOCS)


Doximity (DOCS) Analyst Forecast & Price Prediction

Get the latest Doximity (DOCS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Doximity (DOCS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DOCS stock data and trends